Arcutis Biotherapeutics Inc (ARQT) concluded trading on Thursday at a closing price of $10.14, with 4.39 million shares of worth about $44.56 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -6.11% during that period and on September 19, 2024 the price saw a loss of about -2.50%. Currently the company’s common shares owned by public are about 116.89M shares, out of which, 101.40M shares are available for trading.
Stock saw a price change of -3.61% in past 5 days and over the past one month there was a price change of 20.43%. Year-to-date (YTD), ARQT shares are showing a performance of 213.93% which increased to 55.28% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.76 but also hit the highest price of $13.17 during that period. The average intraday trading volume for Arcutis Biotherapeutics Inc shares is 2.41 million. The stock is currently trading -1.83% below its 20-day simple moving average (SMA20), while that difference is up 2.29% for SMA50 and it goes to 24.41% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) currently have 116.89M outstanding shares and institutions hold larger chunk of about 99.47% of that.
The stock has a current market capitalization of $1.19B and its 3Y-monthly beta is at 1.19. It has posted earnings per share of -$2.18 in the same period. It has Quick Ratio of 8.19 while making debt-to-equity ratio of 1.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ARQT, volatility over the week remained 7.64% while standing at 7.33% over the month.
Stock’s fiscal year EPS is expected to rise by 59.98% while it is estimated to increase by 24.08% in next year. EPS is likely to grow at an annualized rate of 9.80% for next 5-years, compared to annual growth of -48.07% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on August 28, 2024 offering a Buy rating for the stock and assigned a target price of $15 to it. Coverage by Mizuho stated Arcutis Biotherapeutics Inc (ARQT) stock as a Buy in their note to investors on January 03, 2024, suggesting a price target of $8 for the stock. On October 26, 2023, Mizuho Downgrade their recommendations, while on October 13, 2023, Goldman Downgrade their ratings for the stock with a price target of $6. Stock get a Buy rating from Needham on September 07, 2022.
